Loading...
01/10 16:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
Revenue $1.2 million, a growth of 59% over the full year 2023.
Nu.Q Vet Cancer Test Revenue $0.8 million, grew by 75% over the prior year.
Nu.Q Discover Revenue $0.4 million, with year-on-year growth of 40%.
Operating Expenses 23% lower compared to the full year 2023, with second-half operating expenses down 31%.
Net Cash Used in Operating Activities $25.9 million in 2024, compared with $18.1 million in 2023, which benefited from $13 million in milestone payments.
Cash and Cash Equivalents Approximately $3.3 million at the end of the year.
Non-Dilutive Funding Received approximately $1.8 million in non-dilutive funding payments during 2024.
Nu.Q Vet Cancer Test: Expanded access to the Nu.Q Vet cancer test across more than 20 countries, sold approximately 120,000 tests in 2024, resulting in a 75% increase in vet revenue compared to 2023.
Nu.Q Discover: Generated approximately $400,000 in revenue in 2024, with over 2,600 samples processed for 13 customers, including 6 pharmaceutical companies.
Nu.Q NETs: Recorded first revenue for Nu.Q NET, marking a significant milestone.
Market Expansion: Nu.Q Vet Cancer Test is now available in over 20 countries, with significant market penetration achieved in Canada, Australia, New Zealand, the U.K., and several Asian countries.
Licensing Agreements: Strong interest in potential out-licensing and/or supply agreements for Nu.Q NETs and oncology portfolio, with ongoing discussions with multiple large companies.
Operational Efficiencies: Operating expenses were reduced by 23% compared to 2023, with second-half operating expenses down 31%.
Automation of Testing: Signed a deal with Fuji Vet Systems to automate the Nu.Q Vet Cancer test, crucial for scaling operations and increasing revenue.
Strategic Shifts: Focus on signing multiple licensing deals in human diagnostics, leveraging insights from veterinary licensing negotiations.
Regulatory Issues: The company faces uncertainties related to regulatory approvals for its Nu.Q platform and tests, which could impact commercialization timelines.
Competitive Pressures: VolitionRx is operating in a highly competitive market for diagnostic screening and liquid biopsy, which may affect its ability to secure licensing deals and market share.
Supply Chain Challenges: The company has identified the need for automation in centralized labs to scale operations, indicating potential supply chain challenges in meeting increasing demand.
Economic Factors: The company noted that revenues remain 'lumpy and difficult to predict,' suggesting economic factors may influence financial performance and revenue stability.
Cash Flow Risks: VolitionRx aims to be cash-neutral in 2025, but the reliance on licensing agreements and milestone payments introduces risks related to cash flow management.
Licensing Deals: In 2025, VolitionRx aims to sign multiple licensing deals in the human diagnostics space, leveraging insights from previous negotiations in the veterinary sector.
Revenue Growth: The company anticipates ongoing revenue from licensing agreements and aims to replicate the success achieved in the veterinary market.
Market Expansion: VolitionRx is focused on expanding the use of its Nu.Q platform in both oncology and sepsis markets, with significant interest from large companies.
Automation in Labs: The company is prioritizing the automation of centralized labs to scale operations and improve revenue consistency.
Clinical Applications: VolitionRx is working towards having its Nu.Q platform used in regular clinical settings for oncology and NETosis by 2026.
Revenue Expectations: VolitionRx recorded $1.2 million in revenue for 2024, a 59% increase from 2023, with expectations for continued growth.
Operating Expenses: Operating expenses were reduced by 23% in 2024, with a goal to be cash-neutral in 2025.
Future Revenue from Nu.Q Discover: The Nu.Q Discover program is expected to generate significant revenue from a human clinical study sponsored by a leading pharmaceutical company.
Cash Position: Cash and cash equivalents at the end of 2024 totaled approximately $3.3 million, with ongoing non-dilutive funding support.
Guidance for 2025: VolitionRx will not provide specific revenue guidance for 2025 due to the unpredictable nature of early-stage commercialization.
Milestone Payments Received: $23 million in milestone payments received from licensing agreements.
Cash and Cash Equivalents: Approximately $3.3 million in cash and cash equivalents at the end of 2024.
Revenue Growth: Revenue increased by 59% year-on-year, totaling $1.2 million.
Nu.Q Vet Revenue: Revenue from Nu.Q Vet Cancer Test was $0.8 million, a 75% increase over the prior year.
Nu.Q Discover Revenue: Revenue from Nu.Q Discover was approximately $400,000, with year-on-year growth of 40%.
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
The earnings call presents mixed signals. While there are positive aspects like revenue growth, cost management, and milestone payments, the absence of revenue guidance and declining cash position raise concerns. The Q&A section reveals uncertainty in revenue predictability and challenges in maintaining cost levels. Overall, the lack of specific guidance and potential financial risks balance out the positives, suggesting a neutral sentiment towards the stock price movement.
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
